ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening ...

Data Presented at ACAAI Builds Upon Sunovion Legacy in Respiratory Therapies MARLBOROUGH, Mass., Saturday, November 5, 2011 - Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from a ...

In addition to the ciclesonide HFA nasal aerosol data presented at AAAAI, Sunovion also presented a poster titled, “A Post-Hoc Analysis of Asthma Control and Lung Function Following Treatment with ...

The study will enroll 400 patients with symptomatic coronavirus disease 201. A phase 3 study evaluating the efficacy and safety of ciclesonide inhalation aerosol (Alvesco) in non-hospitalized patients ...

With the COVID-19 pandemic, the world has suffered hundreds of thousands of deaths and tens of millions of cases. In order to contain this outbreak, new and already approved drugs are being tested. A ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Nonhospitalized patients with COVID-19 who received the ...

U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco ...

- Sepracor acquires exclusive development, marketing and commercialisation rights to the Ciclesonide franchise in the United States - Ciclesonide is the active ingredient in the ALVESCO® Inhalation ...

Active ingredient: Ciclesonide 80 µg/inhalation, 160 µg/inhalation; metered-dose inhaler. Indication: Maintenance treatment of asthma as prophylactic therapy in patients >12 years of age. Pharmacology ...

At all Walgreens locations, Alvesco will be available at no cost or reduced cost to eligible patients “Asthma is one of the country’s most common diseases, impacting 25 million individuals across the ...